Personalis, Inc. filings document regulatory disclosures for a Nasdaq-listed precision oncology genomics company focused on sequencing, data analysis and cancer monitoring tests. Form 8-K reports cover quarterly and annual operating results, clinical test revenue, business highlights, financial guidance and material events involving NeXT Personal and related reimbursement decisions.
The company’s filings also disclose Medicare coverage and rate determinations for NeXT Personal breast and lung cancer surveillance tests, officer appointments and related compensation arrangements, and the registered common stock traded under PSNL. Proxy materials cover board matters, shareholder voting items, executive compensation and governance disclosures for the public company.
Personalis, Inc. reported Q3 results and liquidity updates. Revenue was $14.5M for the quarter, down from $25.7M a year ago, reflecting lower enterprise and population sequencing activity. Pharma tests and services contributed $13.1M. The company posted a net loss of $21.7M versus a prior-year net loss of $39.1M, which previously included a large noncash warrant fair value charge.
Year‑to‑date revenue was $52.3M versus $67.8M last year, with operating cash use of $52.7M. Cash and cash equivalents were $50.0M and short‑term investments were $100.5M as of September 30, 2025. Shares outstanding were 88,804,348 as of October 28, 2025. During the nine months, the company raised $17.8M net via its ATM program.
Customer concentration remained significant, including contributions from Moderna, Regeneron and Pfizer in the period. The Tempus commercialization agreement continued, with $6.0M in market development fees received and amortizing against promotional costs.
Personalis, Inc. (PSNL) furnished an 8-K under Item 2.02 announcing it issued a press release with financial results for the quarter ended September 30, 2025.
The full text of the release is provided as Exhibit 99.1 and is incorporated herein by reference. The information, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other Securities Act or Exchange Act filings except as expressly set forth by specific reference.
Amendment No. 2 to a Schedule 13D reports that Tempus AI, Inc. beneficially holds 12,718,800 shares of Personalis common stock, representing 14.3% of the outstanding shares based on 88,677,062 shares outstanding. Tempus acquired 9,218,800 shares by exercising warrants for $18,437,600 and purchased 3,500,000 shares from the issuer at $5.07 per share, funded from working capital.
The filing notes that Eric Lefkofsky, as controlling stockholder of Tempus, may be deemed to beneficially own the Tempus-held shares and directly holds 150,000 additional shares, bringing his aggregate to 12,868,800 shares (about 14.5%). The parties amended their Commercialization Agreement to permit Tempus to make open-market purchases up to 19.99% provided other standstill terms are met. A copy of Amendment No. 5 is filed as an exhibit.
Personalis, Inc. (PSNL) filed a Form S-8 to register 350,000 additional common shares (par $0.0001) for issuance under its 2020 Inducement Plan. The filing, made on 5 Aug 2025, brings the total shares available for equity awards to new hires under this Nasdaq-compliant plan up from prior registrations (May 2020 & May 2023) by incorporating those earlier S-8 statements.
The company is classified as a non-accelerated filer and smaller reporting company; therefore, the registration relies on simplified disclosure. No proceeds flow to the company—shares will be issued as restricted stock units or stock options to attract and retain talent. While the aggregate amount is modest (<2% of the 20.4 m shares outstanding at 30 Jun 2025), it adds minor dilution potential and increases equity-based compensation expense over time.